4DMT reels in $90 mln Series B
4D Molecular Therapeutics, a gene therapy company, has raised $90 million in Series B Financing. Viking Global Investors led the round with participation from ArrowMark Partners, Janus Henderson Investors, The Biotechnology Value Fund, MiraeAsset Financial Group, Pappas Capital & Chiesi Ventures, Pfizer Ventures, Perceptive Advisors, Ridgeback Capital Investments, CureDuchenne Ventures and Berkeley Catalyst Fund.
6 September 2018•1 min read
